Melanotan 2 Research, Organized by What It Acts On

Start here

The Melanotan 2 research record is broad but uneven. There is a great deal of animal data and a small amount of human data, and the studies cluster by which receptor is being switched on. Skin studies look at MC1R; appetite and sexual-function studies look at MC4R in the brain.

The sections below follow that structure. Read it as a map of what has been measured, not a recommendation. Where a study used a specific dose, that dose is reported as a fact about how the study was run — Melanotan 2 is not approved for human use ^[3], and nothing here is dosing guidance. Jargon is explained in plain words the first time it appears.

Pigmentation: the original purpose

Melanotan 2 was built to make skin darker without sunlight, and the earliest human study showed it could. In a single-blind, alternating-day, placebo-controlled pilot Phase I study, 3 healthy male volunteers received subcutaneous Melanotan 2 escalated from 0.01 to 0.025-0.03 mg/kg every other weekday for two weeks; 2 of 3 developed increased facial, upper-body, and buttock pigmentation after only five low doses, without UV exposure ^[1]. (These figures describe how the study was conducted; they are not a dosing recommendation, and the compound is not approved for human use.)

The mechanism is eumelanin synthesis — the dark, more photoprotective form of melanin. MC1R activation shifts pigment production toward eumelanin and away from the red-yellow pheomelanin. Preformulation work characterized Melanotan 2 as a cyclic heptapeptide analog of alpha-MSH developed for prevention of sunlight-induced skin cancers, reporting an oral bioavailability of just 4.6% in the rat — which is why it is given by injection rather than by mouth ^[7].

Melanotan 2 tanning

The tanning effect is real and documented, but it comes bundled with the compound's other actions and its harms. The pilot study that produced pigmentation also produced spontaneous erections lasting 1-5 hours and mild nausea ^[1]. In the broader record, the same tanning use is what generated the case reports of darkening moles, eruptive nevi, and melanoma summarized on the Melanotan 2 effects page ^[16]. A historical review frames Melanotan 2 as one of a pair of melanotropic analogs — MT-I for tanning, MT-II tested for both tanning and erectile dysfunction — and traces how the lineage led to a commercialized sexual-function drug ^[3]. The tan is the draw; it is not the whole story.

Appetite and metabolism

Melanotan 2 reliably suppresses appetite in animals, and the studies have localized where. In male C57BL/6J mice, bilateral microinjection of Melanotan 2 directly into the nucleus accumbens (a brain reward region) at 0.1-1 nmol per side significantly decreased food consumption in both home-cage and operant tests and decreased the motivation to work for food — without producing taste aversion or changing metabolic rate ^[5]. The effect is on wanting and eating, not on making the animal sick.

The appetite circuitry can be separated from other axes. In male rats, central co-infusion of Melanotan 2 cancelled most of the appetite-increasing and fat-building effects of neuropeptide Y, but did not reverse NPY's suppression of the reproductive (LH) and growth-hormone axes ^[10] — indicating melanocortin signaling controls appetite and adiposity without modulating those hormonal axes in that model. Sensitivity to the feeding effect also depends on diet: in rats on free-choice diets, central Melanotan 2 suppressed calories most strongly in animals eating a high-saturated-fat diet and preferentially cut the fat component, independent of obesity ^[44].

Sexual function

The sexual effects were an accidental discovery that became a research program. In a double-blind, placebo-controlled crossover study in 10 men with psychogenic erectile dysfunction, subcutaneous Melanotan 2 at 0.025 mg/kg produced clinically apparent erections in 8 of 10 men; the mean duration of greater-than-80% tip rigidity was 38.0 minutes with Melanotan 2 versus 3.0 minutes with placebo (p=0.0045), with transient nausea, stretching, and yawning that needed no treatment ^[2].

A pharmacology review concluded that MC4R is emerging as the principal receptor behind melanocortin-induced erection, with a possible contribution from MC3R, and that these agents may interact with other neurotransmitter systems tied to erection, sexual motivation, and libido ^[8]. This central, brain-driven mechanism — rather than a direct effect on blood vessels — is what distinguishes melanocortin agonists from vascular erectile-dysfunction drugs.

Neurobehavioral and oxytocin signaling

Beyond appetite and erection, Melanotan 2 engages the brain's oxytocin system. Intravenous Melanotan 2 in rats induced Fos expression (a marker of neuronal activation) in magnocellular neurons of the supraoptic and paraventricular hypothalamic nuclei and increased the activity and secretion of oxytocin neurons ^[9] — effects consistent with central melanocortin activation of oxytocin circuitry, which may underlie several of the autonomic and behavioral responses people report, including the stretching and yawning seen in the erectile-dysfunction trial ^[2].

The honest state of the evidence

The human evidence for Melanotan 2 is limited to small Phase I studies of 3 to 20 subjects on pigmentation ^[1] and erectile dysfunction ^[2]. No Phase II or Phase III trial of Melanotan 2 itself has been completed, and it holds no approved indication anywhere ^[3]. The reproducible animal findings — appetite suppression, pro-erectile activity, oxytocin activation — are real and consistent, but they are the first chapter, not the verdict. Set against them are the documented human harms in the case-report literature, which is why this compound is treated as a hazardous research chemical ^[4], ^[36].